MedTrace Logo

UTOLA: UTerin OLAparib

NCT03745950 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2024-12-04

No results posted yet for this study

Summary

This is a phase IIB, national, randomized, double-blinded, comparative, multi-center study, to assess the efficacy of Olaparib as maintenance after a platinum based chemotherapy in patients with Advanced or metastatic endometrial cancer

Conditions

  • Endometrial Carcinoma

Interventions

DRUG

Olaparib Oral Capsule

\- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance

DRUG

Placebo oral capsule

\- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance

Sponsors & Collaborators

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Florence JOLY · GINECO - Centre François Baclesse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2023-05-22
Completion
2024-09-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03745950 on ClinicalTrials.gov